New data from an extensive international clinical trial show that Novo Nordisk’s well-known weight-loss medication Wegovy significantly reduced the risk of having a stroke, having a heart attack, or dying from cardiovascular disease in people without diabetes.
Patients taking semaglutide, the active ingredient in Wegovy as well as Ozempic, for more than three years lost an average of 9.4% of their body weight, compared to the placebo group’s average of 0.9%.
Based on new information provided at the American Heart Association’s scientific conference over the weekend in Philadelphia. They also had a 20% lower risk of a major cardiovascular event.
Fifty percent of the patients received either a placebo or Wegovy weekly during the course of the participants’ average three-year follow-up.
Ozempic along with Wegovy demand is driving up the illegal sales of diet pills.
569 (6.5%) of the patients who received the medication experienced a heart attack, stroke, or died from a heart-related cause, as opposed to 701 (8%), or those who received the dummy shot.
Wegovy Participants Loss Weight
Throughout the course of the study, the Wegovy participants maintained their weight loss gains, losing an average of 10% of their starting weight.
Heart specialist Dr. Martha Gulati of Cedars-Sinai Medical Center in Los Angeles observed that the Wegovy individuals also experienced improvements in their blood pressure, blood sugar, cholesterol, and inflammation.
Novo Nordisk has asked that the FDA list heart benefits on the label for Wegovy, just as they do for Ozempic.
Wegovy is a high-dosage form of Ozempic that has been demonstrated to lower the risk of life-threatening cardiac problems in individuals with diabetes. The fact that this new study focuses on individuals without diabetes is revolutionary.
Participants in the most recent study reported serious adverse reactions, which have been a problem for these types of obesity medications since the beginning.
Due to “adverse events” like nausea, vomiting, and diarrhea, nearly 17% of Wegovy users stopped taking the medication, whereas 8% of the placebo group stopped as well.